159 related articles for article (PubMed ID: 29263041)
21. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls.
Zhang B; Chen JY; Chen DD; Wang GB; Shen P
World J Gastroenterol; 2004 Jun; 10(11):1643-6. PubMed ID: 15162541
[TBL] [Abstract][Full Text] [Related]
22. Proton donor in yeast pyruvate kinase: chemical and kinetic properties of the active site Thr 298 to Cys mutant.
Susan-Resiga D; Nowak T
Biochemistry; 2004 Dec; 43(48):15230-45. PubMed ID: 15568816
[TBL] [Abstract][Full Text] [Related]
23. Kinetic properties of pyruvate kinase in human maternal leukocytes in fetal malnutrition.
Mameesh MS; Metcoff J; Costiloe P; Crosby W
Pediatr Res; 1976 Jun; 10(6):561-5. PubMed ID: 1272633
[TBL] [Abstract][Full Text] [Related]
24. Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation.
Pan Y; Wang W; Huang S; Ni W; Wei Z; Cao Y; Yu S; Jia Q; Wu Y; Chai C; Zheng Q; Zhang L; Wang A; Sun Z; Huang S; Wang S; Chen W; Lu Y
J Cell Mol Med; 2019 Oct; 23(10):6846-6858. PubMed ID: 31343107
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.
Dombrauckas JD; Santarsiero BD; Mesecar AD
Biochemistry; 2005 Jul; 44(27):9417-29. PubMed ID: 15996096
[TBL] [Abstract][Full Text] [Related]
26. Plasma TM2-PK levels in mycosis fungoides patients.
Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis, overexpression, and kinetic characterization of pyruvate kinase from methicillin-resistant Staphylococcus aureus.
Zoraghi R; See RH; Gong H; Lian T; Swayze R; Finlay BB; Brunham RC; McMaster WR; Reiner NE
Biochemistry; 2010 Sep; 49(35):7733-47. PubMed ID: 20707314
[TBL] [Abstract][Full Text] [Related]
28. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
29. Plasma Tumor M2-Pyruvate Kinase Levels in Different Cancer Types.
Muñoz-Colmenero A; Fernández-Suárez A; Fatela-Cantillo D; Ocaña-Pérez E; Domínguez-Jiménez JL; Díaz-Iglesias JM
Anticancer Res; 2015 Jul; 35(7):4271-6. PubMed ID: 26124389
[TBL] [Abstract][Full Text] [Related]
30. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
[TBL] [Abstract][Full Text] [Related]
31. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
32. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Kaura B; Bagga R; Patel FD
J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
[TBL] [Abstract][Full Text] [Related]
34. The allosteric effect of fructose bisphosphate on muscle pyruvate kinase studied by infrared spectroscopy.
Kumar S; Barth A
J Phys Chem B; 2011 Oct; 115(39):11501-5. PubMed ID: 21870844
[TBL] [Abstract][Full Text] [Related]
35. The quaternary structure of pyruvate kinase type 1 from Escherichia coli at low nanomolar concentrations.
Zhu T; Bailey MF; Angley LM; Cooper TF; Dobson RC
Biochimie; 2010 Jan; 92(1):116-20. PubMed ID: 19800933
[TBL] [Abstract][Full Text] [Related]
36. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy.
Hathurusinghe HR; Goonetilleke KS; Siriwardena AK
Ann Surg Oncol; 2007 Oct; 14(10):2714-20. PubMed ID: 17602267
[TBL] [Abstract][Full Text] [Related]
37. Native Mass Spectrometry Gives Insight into the Allosteric Binding Mechanism of M2 Pyruvate Kinase to Fructose-1,6-Bisphosphate.
Gavriilidou AFM; Holding FP; Mayer D; Coyle JE; Veprintsev DB; Zenobi R
Biochemistry; 2018 Mar; 57(11):1685-1689. PubMed ID: 29499117
[TBL] [Abstract][Full Text] [Related]
38. Synergistic Allosteric Mechanism of Fructose-1,6-bisphosphate and Serine for Pyruvate Kinase M2 via Dynamics Fluctuation Network Analysis.
Yang J; Liu H; Liu X; Gu C; Luo R; Chen HF
J Chem Inf Model; 2016 Jun; 56(6):1184-1192. PubMed ID: 27227511
[TBL] [Abstract][Full Text] [Related]
39. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
40. Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.
Dhar DK; Olde Damink SW; Brindley JH; Godfrey A; Chapman MH; Sandanayake NS; Andreola F; Mazurek S; Hasan T; Malago M; Pereira SP
Cancer; 2013 Feb; 119(3):575-85. PubMed ID: 22864959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
